Uncategorized Archives - Page 42 of 142

FridayOct 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for onward travel into the brain Odyssey’s just concluded Phase I clinical trial shows that PRV-002 is safe and well tolerated The findings from the study are likely to benefit the military as well as the NFL, given military personnel and players frequently suffer concussions In…

MondayOct 10, 2022 9:00 am

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the players According to a report published by Vox, there are approximately 0.41 concussions per NFL game in American football, with 9.3% of concussions involving the loss of consciousness and 2.4% resulting in hospitalizations With such cases, there is a need to revise the NFL’s concussion…

ThursdayOct 06, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing…

WednesdayOct 05, 2022 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering,…

TuesdayOct 04, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002 This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial…

MondayOct 03, 2022 10:45 am

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart…

WednesdaySep 28, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments The company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life Scientists and specialists describe concussion, which is also referred to as mild traumatic brain injury (“mTBI”), as a spectrum. On the one hand, some concussed patients fully recover and do not require medical intervention or attention; on the other,…

TuesdaySep 27, 2022 10:30 am

NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%

A lot of football players often suffer concussions because their sports usually involve contact. Concussions are brain injuries caused by a blow to an individual’s head, which may or may not result in the loss of consciousness. These injuries sometimes cause temporary cognitive symptoms and have no specific cure. Concussion symptoms include confusion, headaches, loss of memory, lack of coordination, nausea and vomiting, ringing in the ears, dizziness, excessive fatigue and sleepiness. Data from a 2017 study found that 99% of tested NFL players, 91% of college football players and 88% of CFL players suffered from various stages of chronic…

MondaySep 26, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailments Odyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to commercial fulfillment The therapeutic solution, currently known as PRV-002, is designed to deliver a synthetic neurosteroid to injured brain tissue, where it can reduce swelling and sustain needed blood flow The company’s human testing has demonstrated safety with “no serious adverse events,” and Odyssey is…

FridaySep 23, 2022 10:30 am

Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs

Endometriosis is a disorder that causes the tissue that lines the inside of the uterus to grow outside the reproductive organ. It is associated with menstrual irregularities and pain and is estimated to affect around 10% of American women of reproductive age. The condition develops into endometrial cancer when the endometrial cells grow out of control, leading to the development of a tumor. Unfortunately, there is no cure for endometriosis, and current treatments can only do so much to ease the condition’s symptoms so they don’t interfere with an individual’s day-to-day activities. Prior studies have found that patients with endometrial…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search